Advanced search×

In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor.

Mol Pharmacol 80(1):32-9 (2011) PMID 21454448

The development of vectors for drug delivery to the central nervous system remains a major pharmaceutical challenge. Here, we have characterized the brain distribution of two monoclonal antibodies (MAbs) targeting the mouse transferrin receptor (TfR) (clones Ri7 and 8D3) compared with control IgGs after intravenous injection into mice. MAbs were fluorolabeled with either Alexa Fluor (AF) dyes 647 or 750. Intravenous injection of Ri7 or 8D3 MAb coupled with AF750 led to higher fluorescence emission in brain homogenates compared with control IgGs, indicating retention in the brain. Fluorescence microscopy analysis revealed that AF647-Ri7 signal was confined to brain cerebrovasculature, colocalizing with an antibody against collagen IV, a marker of basal lamina. Confocal microscopy analysis confirmed the delivery of injected Ri7 MAb into brain endothelial cells using the pericyte marker anti-α-smooth muscle actin, the endothelial marker CD31, and the collagen IV antibody. No evidence of colocalization was detected with neurons or astrocytes identified using antibodies specific for neuronal nuclei or glial fibrillary acidic protein, respectively. Our data show that anti-TfR vectors injected intravenously readily accumulate into brain capillary endothelial cells, thus displaying strong drug-targeting potential.

DOI: 10.1124/mol.111.071027
Version: za2963e q8za4 q8zbd q8zc1 q8zda q8ze6 q8zf4 q8zg4

Similar articles you may find interesting…

  1. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

    Clin Cancer Res 17(8):2207-15 (2011) PMID 21385922

    To evaluate the effect of rituximab monoclonal antibody (mAb) on MRI tumor volumetrics and efficacy in a rat model of central nervous system (CNS) lymphoma when delivery to the brain was optimized with osmotic blood-brain barrier disruption (BBBD). Female nude rats with intracerebral MC116 human B-ce...
  2. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

    Clin Cancer Res 17(8):2207-15 (2011) PMID 21385922

    Rituximab was effective at decreasing tumor volume and improving survival in a CNS lymphoma model, and was not affected by combination with methotrexate or by BBBD. We suggest that rituximab warrants further study in human primary CNS lymphoma....
  3. The role of immunity in Huntington's disease.

    Mol Psychiatry 16(9):889-902 (2011) PMID 21519341

    We attempt to bring a novel understanding to the interaction of the immune system to HD pathology, thereby shedding light on its potential pathogenic role. As part of this discussion, we revisit the clinical data on the anti-inflammatory drug trials in HD and propose new experimental approaches to i...